Discover Daiichi Sankyo's groundbreaking patent for monoclonal antibodies targeting LAG-3, offering new hope for treating autoimmune diseases with enhanced efficacy.
DaiichiSankyo (OTCPK:DSKYF)(OTCPK:DSNKY) reports that more than 97% of eligible claimants have opted into the product liability settlement program related to olmesartan products... Daiichi ...
Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.
Some results have been hidden because they may be inaccessible to you